Consistent with these findings, treatment of Wnt/β-catenin inhibitor suppressed NLGN3 expression, and combination therapy using temozolomide and Wnt/β-catenin inhibitor showed significantly enhanced therapeutic efficacy of GBM. This evidence concerns the gene NLGN3 and glioblastoma.